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B ilirubin can cross the blood-brain barrier, especiallywhen plasma concentrations are high and in neo-
nates. Bilirubin is toxic and can lead to irreversible
brain damage, signs of neurologic disease, and coma,
which is called “kernicterus.”
The most important cause of clinical icterus in equine
neonates is neonatal isoerythrolysis (NI), an alloim-
mune disease characterized by immune-mediated hemo-
lytic anemia and, consequently hyperbilirubinemia and
hypoxia. Prognosis generally is guarded to good, but
when NI leads to kernicterus, chances for survival are
low.1 Treatment of NI consists of supportive care and
blood transfusions, but none of these lower plasma bili-
rubin concentration. In human medicine, therapeutic
plasma exchange has been successfully used in cases of
hyperbilirubinemia.2–4
This case report describes 2 foals that were examined
because of severe anemia and hyperbilirubinemia
because of NI. Despite treatment, bilirubin concentra-
tions continued to rise in the ﬁrst 48 hours. Because of
the risk of the development of kernicterus, plasma
exchange treatment was performed with a commercial
plasmapheresis device. Both foals had an immediate
decrease (44 and 57%) in plasma bilirubin concentra-
tion and fully recovered.
Case Presentation
A 2-day-old warmblood colt was presented with com-
plaints of icterus, weakness, and hemoglobinuria. The
foal was born healthy and nursed well for the ﬁrst
2 days. IgG concentrations 24 hours after birth were
more than 8 g/L. On the morning before arrival, the
foal was found to be lethargic and reluctant to drink,
and his condition quickly deteriorated during that day.
Upon arrival at the University hospital, the foal was in
lateral recumbency. There was no reaction to external
stimuli. Skin turgor and capillary reﬁll time were
severely lethargic. Mucous membranes were yellow and
dry. Laboratory abnormalities included severe anemia
(PCV 9%, normal values 30–45%), moderate metabolic
acidosis, and hyperbilirubinemia (total bilirubin
365 lmol/L, normal values 0–80 lmol/L). The pre-
sumptive diagnosis was NI. The foal received 3 L of
blood from a donor gelding at arrival; no cross match
tests were performed before transfusion. After the trans-
fusion, the foal regained consciousness, the sucking
reﬂex returned, and he was able to stand and walk.
PCV was 18% but bilirubin concentration had not
changed. The foal was further treated with Ringer’s lac-
tate (4 mL/kg/h IV), oxygen (6 L/min), broad spectrum
antibiotics (Cefquinome,a 2 mg/kg q12h), and vitamin
E and selenium supplements. He was separated from
the mare and received milk replacer every hour. Six
hours after the transfusion, the foal’s condition started
to slowly deteriorate and 12 hours after the transfusion,
the foal again was very weak and unable to rise. PCV
had dropped to 10%. The foal received 2 L of washed
red blood cells from the mare and after this 2nd trans-
fusion, his behavior markedly improved. He regained
activity, was alert, and able to rise and suckle. Total bil-
irubin plasma concentrations however continued to rise,
reaching 466 lmol/L 2 days after arrival at the clinic.
To reduce the risk of the development of kernicterus,
plasma exchange treatment was performed with a com-
mercial plasmapheresis device and 3 L of donor plasma.
Plasma exchange resulted in an immediate decrease in
total plasma bilirubin from 466 lmol/L to 261 lmol/L
(Table 2). Neurologic signs did not develop and the foal
fully recovered. Ten days after their arrival at the clinic,
foal and mare could return home.
The 2nd foal, a 5-day-old warmblood ﬁlly, was exam-
ined because of icterus and weakness. The foal was
born healthy and immediately nursed well. Five days
after birth, she was found icteric and reluctant to rise.
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Upon arrival at the clinic, the foal was standing, but
lethargic and weak. Mucous membranes were yellow
and dry, skin turgor and capillary reﬁll time diminished.
Blood examination revealed severe anemia (PVC 10%),
severe acidosis (pH: 7.08, BE: 15, bicarbonate:
13.2 mmol/L), hyperbilirubinemia (total bilirubin
398 lmol/L), moderate hypoglycemia, and leukocytosis.
The presumptive diagnosis was NI. The foal received
2 L of blood from a donor gelding. After the transfu-
sion, the foal’s general condition improved, she was
active and alert and able to suckle from the mare.
Treatment was continued with Ringer’s lactate
(4 mL/kg/h IV), glucose (4 mg/kg/h), and broad spec-
trum antibiotics (Cefquinome,a 2 mg/kg q12h). The fol-
lowing day, total plasma bilirubin concentration had
increased to 445 lmol/L and plasma exchange treat-
ment was performed to reduce the risk for development
of kernicterus. Three liters of plasma were replaced with
plasma from a donor horse. The day after the proce-
dure, total bilirubin concentration had decreased to
191 lmol/L. The foal was alert and nursing, nervous
signs did not develop. After 5 days, foal and mare left
the clinic in good health.
Materials and Methods
In both horses, a 16-gauge catheter was aseptically inserted in
the left jugular vein. This catheter was connected to a commercial
plasmapheresis device (Baxter Fenwall, model 200). This device,
commonly used in human medicine, withdraws blood from the
patient and automatically separates plasma from red blood cells
(RBC) by ﬁltration. Approximately, 300 mL of blood at a time is
withdrawn over a time period of 3 minutes, anticoagulant (antico-
agulant citrate dextrose solution,b 3 mg/mL) is automatically
added and plasma and RBC are separated. After separation, RBC
are returned to the patient, plasma is collected in separate bags,
and the cycle recommences. One cycle takes between 10 and
15 minutes. In both foals, a pediatric long-term catheter (Certoﬁx
Mono, Braunc,d ) was already present in the right jugular vein for
the administration of ﬂuids and antibiotics. This catheter was also
used to administer donor plasma during the plasma exchange pro-
cedure. In both foals, a total of 3,000 mL plasma was removed
and simultaneously the same amount of plasma from a donor
horse was administered. The ﬁrst 300 mL of donor plasma was
given slowly over 45 minutes, with close monitoring of the foal’s
vital signs. If no signs of transfusion reaction occurred, the
remaining plasma was given at a rate of approximately
1,000 mL/h. The total plasma exchange procedure lasted approxi-
mately 4 hours, whereby the foals were kept in lateral recumbency.
Both foals were calm and cooperative and no sedatives were used.
After the procedure, the short-term catheter from the left vein was
removed and a cotton bandage placed to avoid bleeding and
swelling of the catheter entrance site. The right catheter was left in
place to be used for further intravenous treatments.
Discussion
In horses, 1 study showed that foals with a total bili-
rubin concentration above 461.7 lmol were 17 times
more likely to develop kernicterus than foals with a
lower total bilirubin.1 Although not all foals with total
bilirubin concentrations above 461.7 lmol/L will
develop kernicterus, beneﬁts of plasma exchange may
outweigh the risk of the procedure, if total bilirubin
concentrations approach this cut-oﬀ value. Because
total bilirubin concentrations of both our foals
approached the cut-oﬀ value and bilirubin concentra-
tions continued to increase, we decided to perform a
plasma exchange procedure. However, it is unknown
whether kernicterus would have developed if this tech-
nique would not have been used.
In humane medicine, plasmapheresis is used to lower
bilirubin concentrations in the blood of patients at risk
of developing kernicterus. Its use has been described in
neonatal babies as well as in adults with extreme hyper-
bilirubinemia.2–4 Plasmapheresis refers to the extracor-
poreal ﬁltration of blood, to remove plasma from, and
return RBC to the circulation. If the removed plasma is
replaced with plasma from a donor, the technique is
called plasma exchange. In human medicine, plasma-
pheresis and plasma exchange are routinely used for the
removal of toxic substances from the circulation. Next
to auto-immune disorders, where the rapid removal of
disease-causing autoantibodies from the circulation is
required, plasmapheresis or plasma exchange is used for
a variety of other disorders, such as hyperviscosity syn-
drome, hemolytic uremic syndrome, and intoxications.5
In horses, the use of plasma exchange has not been
studied. Although our cases showed a clear decrease in
plasma bilirubin concentrations after plasma exchange,
more controlled studies are necessary to assess the bene-
ﬁt of this treatment in foals.
Three diﬀerent techniques for plasmapheresis exist:
continuous ﬂow centrifugation, discontinuous ﬂow cen-
trifugation, and plasma ﬁltration.5 In our cases, discon-
tinuous ﬂow centrifugation was used. With this
technique, blood is intermittently withdrawn and RBC
intermittently returned via the same catheter. A 300-mL
batch of blood is removed at a time and centrifuged,
and in human medicine such large quantity hampers the
use of this technique in babies. In a 50-kg warmblood
foal, withdrawal of 300 mL of blood was not expected
to result in an important cardiovascular compromise. In
small foals or when the withdrawal of 300 mL blood is
expected to cause cardiovascular problems, a plasma ﬁl-
tration technique should be used. This technique, espe-
cially designed for babies, uses 2 venous lines and only
removes 50 mL of blood at a time from the body.
Although plasmapheresis and plasma exchange are
considered safe techniques, complications have been
reported. Most common complications involve the
placement of a catheter (bleeding, infection) and sub-
clinical to clinical hypocalcemia. When patient blood is
outside of the body passing through the plasmapheresis
machine, the blood has a tendency to clot. To reduce
this tendency, citrate is infused while the blood is
running through the circuit. Citrate binds to calcium,
an important factor in blood coagulation. Citrate is
very eﬀective in preventing blood from clotting, but can
lead to life-threatening hypocalcemia, an important
complication of plasmapheresis and plasma exchange in
6% of human patients.5,7,8 Monitoring and treating
hypocalcemia is therefore important during the proce-
dure. Neither of our cases developed hypocalcemia dur-
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ing or after the plasma exchange procedure. Other com-
plications include hypotension, immune suppression,
and clot formation.5,7 In 3 studies evaluating plasma-
pheresis in horses, no adverse eﬀects were noted.6–8
Plasma exchange requires the use of donor plasma and
as such, the additional risks of adverse reactions or of
transmitting an infectious disease. Ideally, plasma
donors should be kept in isolation and thoroughly
tested for infectious diseases. Alternatively, commer-
cially available plasma can be used. To minimize the
risk of transfusion reactions, compatibility testing can
be done before performing plasma transfer. In our case,
no compatibility tests were performed. The ﬁrst 300 mL
of plasma was given slowly while the foals were closely
monitored for signs of incompatibility. Fresh frozen
plasma of gelding donors was used to reduce the risk
for transfusion reactions. As plasma exchange takes
time, it requires restraint of the foal to avoid dislodge-
ment of the tubings. Our foals were kept in lateral
recumbency by manual restraint throughout the proce-
dure. As they tolerated this procedure well, we chose
not to administer sedatives. Alternatively, low-dose sed-
atives could be used or the foals could be placed in a
small box next to the machine to limit movement. Nei-
ther of the 2 foals showed a change in behavior during
or after the procedure. Of plasma, 3,000 mL was
exchanged with an immediate decrease in more than
50% in plasma bilirubin concentration. Kernicterus did
not develop and both foals recovered completely.
Footnotes
a Cobactan 4,5%, MSD Animal Health BVBA, Lynx Binnenhof 5,
1200 Brussel, Belgium
b ACD-A, anticoagulant citrate dextrose solution 500 mL, Fenwal
Europe sprl, Rue Edouard Belin 2-4, 1435 Mont Saint Guibert,
Belgium
c Certoﬁx Mono V320 16G, B. Braun Melsungen, Carl Braun
Strase 1, 34209 Melsungen, Germany
d SNAP Foal IgG test, IDEXX Europe B.V., Scorpius 60 Building
F, Hoofddorp, 2132LR, The Netherlands
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